Cargando…

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015

PURPOSE: Lower respiratory tract infections (LRTIs) can cause significant morbidity and mortality and are becoming increasingly difficult to treat because of the growing prevalence of resistance to conventional antimicrobial agents. This study aimed to assess the current in vitro susceptibility of r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santerre Henriksen, Anne, Smart, Jennifer I, Hamed, Kamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118268/ https://www.ncbi.nlm.nih.gov/pubmed/30214251 http://dx.doi.org/10.2147/IDR.S176369

Ejemplares similares

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015
por: Henriksen, Anne Santerre, et al.
Publicado: (2018)

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)
por: Canton, Rafael, et al.
Publicado: (2022)

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials
por: Scheeren, Thomas W. L., et al.
Publicado: (2019)

1240. Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020
por: Duncan, Leonard R, et al.
Publicado: (2021)

1595. Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019
por: Duncan, Leonard R, et al.
Publicado: (2020)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
por: Flamm, Robert K, et al.
Publicado: (2017)

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Safety and tolerability of ceftobiprole
por: Grau, Santiago
Publicado: (2019)

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
por: Hamed, Kamal, et al.
Publicado: (2020)

Possible clinical indications of ceftobiprole
por: Barberán, José
Publicado: (2019)

Ceftobiprole: a clinical view
por: Pérez-Crespo, Pedro María Martínez, et al.
Publicado: (2021)

1043. Activity of Mecillinam Against Enterobacterales Isolates Collected From Patients With Urinary Tract Infections (UTIs) in the USA During 2019
por: Hawser, Stephen, et al.
Publicado: (2021)

A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients
por: Bosheva, Miroslava, et al.
Publicado: (2021)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Mechanisms of action and antimicrobial activity of ceftobiprole
por: Morosini, María-Isabel, et al.
Publicado: (2019)

Ceftobiprole for the treatment of pneumonia: a European perspective
por: Liapikou, Adamantia, et al.
Publicado: (2015)

Ceftobiprole Perspective: Current and Potential Future Indications
por: Lupia, Tommaso, et al.
Publicado: (2021)

The epidemiology and estimated etiology of pathogens detected from the upper respiratory tract of adults with severe acute respiratory infections in multiple countries, 2014–2015
por: Milucky, Jennifer, et al.
Publicado: (2020)

Further description of bovine tuberculosis trends in the United Kingdom and the Republic of Ireland, 2003–2015
por: More, Simon J, et al.
Publicado: (2018)

1617. Mecillinam susceptibility against Enterobacterales isolated from urinary tract infections from US patients in 2018
por: Hawser, Stephen, et al.
Publicado: (2020)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

Erratum to: In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
por: Hamed, Kamal, et al.
Publicado: (2020)

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
por: Cammarata, Anthony P, et al.
Publicado: (2023)

Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia
por: Hahn, Mark M., et al.
Publicado: (2023)

1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

2162. In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole
por: Bustos, César, et al.
Publicado: (2010)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non‐Asian Subjects
por: Muller, A. E., et al.
Publicado: (2018)

Alcohol consumption among university students in Ireland and the United Kingdom from 2002 to 2014: a systematic review
por: Davoren, Martin P., et al.
Publicado: (2016)

Impact of PBP4 Alterations on β-Lactam Resistance and Ceftobiprole Non-Susceptibility Among Enterococcus faecalis Clinical Isolates
por: Lazzaro, Lorenzo M., et al.
Publicado: (2022)

The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015
por: Brown, Katrina F., et al.
Publicado: (2018)

Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)
por: Overcash, J Scott, et al.
Publicado: (2020)

Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole
por: Barbour, April, et al.
Publicado: (2010)

Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series
por: Mahmoud, Ebrahim, et al.
Publicado: (2020)

1428. Increased Consumption of Pivmecillinam in Primary Care for Uncomplicated Urinary Tract Infection (uUTI) Is Not Associated With Increased Resistance Rates
por: Larsen, Anders Rhod, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u14mbmb5p7vtcd8905usrs4nln